Kovitz Investment Group Partners LLC Has $469.89 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Kovitz Investment Group Partners LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,905.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 903,232 shares of the medical research company's stock after acquiring an additional 858,193 shares during the quarter. Thermo Fisher Scientific accounts for 1.6% of Kovitz Investment Group Partners LLC's investment portfolio, making the stock its 22nd biggest position. Kovitz Investment Group Partners LLC owned 0.24% of Thermo Fisher Scientific worth $469,889,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $28,000. FPC Investment Advisory Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TMO. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Scotiabank lowered their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Raymond James reissued an "outperform" rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $610.27.

Thermo Fisher Scientific Stock Down 0.3 %

Shares of Thermo Fisher Scientific stock traded down $1.25 on Wednesday, hitting $426.28. 756,330 shares of the company traded hands, compared to its average volume of 1,748,870. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a 50-day moving average price of $482.87 and a 200 day moving average price of $524.80. The company has a market cap of $160.92 billion, a PE ratio of 25.79, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business earned $5.11 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.